KR100640025B1 - 3-(시클로프로필메톡시)-ｎ-(3,5-디클로로-4-피리디닐)-4-(디플루오로메톡시)벤즈아미드 및 폐 계면활성제를 포함하는 성인성호흡 곤란 증후군 및 영아 호흡 장애 증후군을 치료하기 위한 조성물 - Google Patents

3-(시클로프로필메톡시)-ｎ-(3,5-디클로로-4-피리디닐)-4-(디플루오로메톡시)벤즈아미드 및 폐 계면활성제를 포함하는 성인성호흡 곤란 증후군 및 영아 호흡 장애 증후군을 치료하기 위한 조성물 Download PDF

Info

Publication number
KR100640025B1
KR100640025B1 KR1019997007400A KR19997007400A KR100640025B1 KR 100640025 B1 KR100640025 B1 KR 100640025B1 KR 1019997007400 A KR1019997007400 A KR 1019997007400A KR 19997007400 A KR19997007400 A KR 19997007400A KR 100640025 B1 KR100640025 B1 KR 100640025B1
Authority
KR
South Korea
Prior art keywords
cyclopropylmethoxy
surfactant
ards
lung
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019997007400A
Other languages
English (en)
Korean (ko)
Other versions
KR20000071112A (ko
Inventor
게르만파울-게오르그
킬리안울리히
보이메롤프
암슐러헤르만
크뤼거우베
해프너디트리히
아이스테터클라우스
Original Assignee
알타나 파마 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19705924A external-priority patent/DE19705924A1/de
Application filed by 알타나 파마 아게 filed Critical 알타나 파마 아게
Publication of KR20000071112A publication Critical patent/KR20000071112A/ko
Application granted granted Critical
Publication of KR100640025B1 publication Critical patent/KR100640025B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
KR1019997007400A 1997-02-17 1998-02-14 3-(시클로프로필메톡시)-ｎ-(3,5-디클로로-4-피리디닐)-4-(디플루오로메톡시)벤즈아미드 및 폐 계면활성제를 포함하는 성인성호흡 곤란 증후군 및 영아 호흡 장애 증후군을 치료하기 위한 조성물 Expired - Fee Related KR100640025B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19705924A DE19705924A1 (de) 1997-02-17 1997-02-17 Neue Zusammensetzungen
DE19705924.4 1997-02-17
EP97102639.8 1997-02-19
EP97102639 1997-02-19
PCT/EP1998/000847 WO1998035683A1 (en) 1997-02-17 1998-02-14 Compositions for the treatment of ards or irds containing 3-(cyclopropylmethoxy)-n-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide and lung surfactant

Publications (2)

Publication Number Publication Date
KR20000071112A KR20000071112A (ko) 2000-11-25
KR100640025B1 true KR100640025B1 (ko) 2006-10-31

Family

ID=26033977

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019997007400A Expired - Fee Related KR100640025B1 (ko) 1997-02-17 1998-02-14 3-(시클로프로필메톡시)-ｎ-(3,5-디클로로-4-피리디닐)-4-(디플루오로메톡시)벤즈아미드 및 폐 계면활성제를 포함하는 성인성호흡 곤란 증후군 및 영아 호흡 장애 증후군을 치료하기 위한 조성물

Country Status (25)

Country Link
US (2) US6436970B1 (enExample)
EP (1) EP0977577B1 (enExample)
JP (1) JP4763104B2 (enExample)
KR (1) KR100640025B1 (enExample)
CN (1) CN1123345C (enExample)
AT (1) ATE336254T1 (enExample)
AU (1) AU734122B2 (enExample)
BR (1) BR9807399B1 (enExample)
CA (1) CA2276429C (enExample)
CZ (1) CZ293871B6 (enExample)
DE (1) DE69835594T2 (enExample)
DK (1) DK0977577T3 (enExample)
EA (1) EA001758B1 (enExample)
EE (1) EE04094B1 (enExample)
ES (1) ES2271990T3 (enExample)
HU (1) HU227520B1 (enExample)
IL (1) IL130658A (enExample)
NO (1) NO323594B1 (enExample)
NZ (1) NZ336569A (enExample)
PL (1) PL190775B1 (enExample)
PT (1) PT977577E (enExample)
SI (1) SI0977577T1 (enExample)
TR (1) TR199901772T2 (enExample)
UA (1) UA50808C2 (enExample)
WO (1) WO1998035683A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TR199901772T2 (enExample) * 1997-02-17 1999-09-21 Byk Gulden Lomberg Chemische Fabrik Gmbh
JP2001081031A (ja) * 1999-08-30 2001-03-27 Schering Ag 溶解性および経口吸収性を改善したベンズアミド誘導体含有製剤
EP1216052A1 (en) * 1999-09-16 2002-06-26 Byk Gulden Lomberg Chemische Fabrik GmbH Combination of c1-inh and lung surfactant for the treatment of respiratory disorders
DE19957898A1 (de) * 1999-12-01 2001-06-07 Byk Gulden Lomberg Chem Fab Neue Verwendung von Lungensurfactant
JP2003534328A (ja) 2000-05-25 2003-11-18 メルク フロスト カナダ アンド カンパニー フルオロアルコキシ置換ベンズアミドジクロロピリジニルｎ−オキシドｐｄｅ４阻害剤
WO2002094823A1 (en) 2001-05-24 2002-11-28 Merck Frosst Canada & Co. 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors
US20030099601A1 (en) * 2001-11-27 2003-05-29 Gordon Marc S. Inhalation lung surfactant therapy
WO2003053455A1 (en) * 2001-12-12 2003-07-03 Penn State Research Foundation Surfactant prevention of lung complications from cancer chemotherapy
US20030170223A1 (en) * 2002-02-01 2003-09-11 Board Of Trustees Of Michigan State University Pulmonary vasodilator surfactant compositions and method of use
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
US6822114B1 (en) 2002-10-08 2004-11-23 Albemarle Corporation Process for production of fluoroalkoxy-substituted benzamides and their intermediates
PL214869B1 (pl) * 2002-11-27 2013-09-30 Nycomed Gmbh Synergistyczna kombinacja zawierajaca roflumilast i (R, R)-formoterol
WO2004047829A1 (en) * 2002-11-27 2004-06-10 Altana Pharma Ag New synergistic combination comprising roflumilast and formoterol
ES2335498T3 (es) 2003-03-10 2010-03-29 Nycomed Gmbh Nuevo proceso para la preparacion de reflumilast.
US7238664B2 (en) 2003-06-16 2007-07-03 Altana Pharma Ag Composition comprising a pulmonary surfactant and a PDE5 inhibitor for the treatment of lung diseases
EP1781323B1 (en) 2004-08-06 2010-02-17 Nycomed GmbH Composition comprising a pulmonary surfactant and a tnf-derived peptide
EP2258350B1 (en) * 2005-03-16 2014-12-24 Takeda GmbH Taste masked dosage form containing roflumilast
CN101657460A (zh) * 2006-12-13 2010-02-24 基利得科学公司 用于治疗肺炎症和支气管收缩的作为抗炎性信号转导调节剂(AISTM’S)和β-激动剂的相互前药的单磷酸酯
WO2009055788A1 (en) * 2007-10-26 2009-04-30 Aeris Therapeutics, Inc. Pneumoreductive therapy and compositions useful therein
US20160199413A1 (en) * 2013-08-01 2016-07-14 Isletone Ab Mscs in the treatment of inflammatory pulmonary diseases
CN104800214A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入气雾剂复方及制备方法
RU2728821C1 (ru) * 2020-05-13 2020-07-31 Федеральное государственное бюджетное учреждение науки "Научный центр биомедицинских технологий Федерального медико-биологического агентства" (ФГБУН НЦБМТ ФМБА России) Способ лечения острого респираторного дистресс-синдрома даларгином и легочным сурфактантом

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451215A1 (en) * 1988-12-29 1991-10-16 Bradley J Benson PULMONARY ADMINISTRATION OF PHARMACEUTICALLY ACTIVE SUBSTANCES.
WO1995001338A1 (de) * 1993-07-02 1995-01-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4223040A (en) * 1974-11-26 1980-09-16 Carroll John M Lauric acid for the prevention and treatment of mycobacterial diseases
JPS5795920A (en) * 1980-12-04 1982-06-15 Teijin Ltd Remedy for respiratory disease
JPS5845299A (ja) * 1981-09-10 1983-03-16 東京田辺製薬株式会社 新規な表面活性物質、その製造法及びそれを含有する呼吸窮迫疾候群治療剤
ES532337A0 (es) * 1983-05-11 1985-12-01 Byk Gulden Lomberg Chem Fab Procedimiento para la preparacion de 6-aril-3 (2h)piridazinonas
US4906476A (en) * 1988-12-14 1990-03-06 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs in lungs
US5856196A (en) * 1993-10-25 1999-01-05 Beth Israel Hospital Processes for quantitating phosphoglycerides in a lipid mixture and diagnostic uses therefor
GB9401460D0 (en) 1994-01-26 1994-03-23 Rhone Poulenc Rorer Ltd Compositions of matter
DE4434629C1 (de) * 1994-09-28 1996-06-27 Byk Gulden Lomberg Chem Fab Zusammensetzungen zur Behandlung von IRDS und ARDS
US5531219A (en) * 1994-11-04 1996-07-02 Alliance Pharmaceutical Corp. Use of liquid fluorocarbons to facilitate pulmonary drug delivery
US5698537A (en) * 1996-06-18 1997-12-16 Clarion Pharmaceuticals Inc. Method of lowering the viscosity of mucus
TR199901772T2 (enExample) * 1997-02-17 1999-09-21 Byk Gulden Lomberg Chemische Fabrik Gmbh
US6180142B1 (en) * 1998-08-21 2001-01-30 The Regents Of The University Of California Reduction of surfactant inactivation in pulmonary surfactant therapy
EP1206326A1 (en) * 1999-06-29 2002-05-22 L-Tech Corporation Chemical film cleaning and drying

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0451215A1 (en) * 1988-12-29 1991-10-16 Bradley J Benson PULMONARY ADMINISTRATION OF PHARMACEUTICALLY ACTIVE SUBSTANCES.
WO1995001338A1 (de) * 1993-07-02 1995-01-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Fluoralkoxy substituierte benzamide und ihre verwendung als zyklisch-nukleotid phosphodiesterase-inhibitoren

Also Published As

Publication number Publication date
HUP0001043A3 (en) 2002-12-28
NO323594B1 (no) 2007-06-11
EP0977577A1 (en) 2000-02-09
DE69835594T2 (de) 2007-08-16
EP0977577B1 (en) 2006-08-16
PL335134A1 (en) 2000-04-10
EE04094B1 (et) 2003-08-15
CA2276429A1 (en) 1998-08-20
IL130658A (en) 2004-07-25
PT977577E (pt) 2007-02-28
EA001758B1 (ru) 2001-08-27
UA50808C2 (uk) 2002-11-15
BR9807399B1 (pt) 2011-04-19
WO1998035683A1 (en) 1998-08-20
ES2271990T3 (es) 2007-04-16
TR199901772T2 (enExample) 1999-09-21
AU734122B2 (en) 2001-06-07
CZ293871B6 (cs) 2004-08-18
SI0977577T1 (sl) 2007-02-28
HUP0001043A2 (hu) 2000-09-28
HU227520B1 (hu) 2011-07-28
EE9900279A (et) 2000-02-15
CN1123345C (zh) 2003-10-08
US6436970B1 (en) 2002-08-20
NO993875L (no) 1999-08-11
BR9807399A (pt) 2000-03-14
DK0977577T3 (da) 2006-12-18
EA199900645A1 (ru) 2000-04-24
IL130658A0 (en) 2000-06-01
KR20000071112A (ko) 2000-11-25
JP2001512452A (ja) 2001-08-21
US6998410B2 (en) 2006-02-14
CA2276429C (en) 2007-06-19
NO993875D0 (no) 1999-08-11
HK1026145A1 (en) 2000-12-08
NZ336569A (en) 2001-04-27
AU6497398A (en) 1998-09-08
PL190775B1 (pl) 2006-01-31
CZ291499A3 (cs) 2000-02-16
US20020132835A1 (en) 2002-09-19
JP4763104B2 (ja) 2011-08-31
ATE336254T1 (de) 2006-09-15
DE69835594D1 (de) 2006-09-28
CN1248169A (zh) 2000-03-22

Similar Documents

Publication Publication Date Title
KR100640025B1 (ko) 3-(시클로프로필메톡시)-ｎ-(3,5-디클로로-4-피리디닐)-4-(디플루오로메톡시)벤즈아미드 및 폐 계면활성제를 포함하는 성인성호흡 곤란 증후군 및 영아 호흡 장애 증후군을 치료하기 위한 조성물
US7053176B1 (en) Combination of C1-INH and lung surfactant for the treatment of respiratory disorders
EP1131055B1 (en) Treatment set containing lungsurfactant compositions
US7247317B2 (en) Compositions comprising phenylaminothiophenacetic acid derivatives for the treatment of acute or adult respiratory distress syndrome (ARDS) and infant respiratory distress syndrome (IRDS)
JP2003522138A (ja) 慢性肺疾患の予防および治療のための肺表面活性剤の新規使用
JP4503835B2 (ja) 急性または成人型呼吸窮迫症候群（ａｒｄｓ）および新生児呼吸窮迫症候群（ｉｒｄｓ）の治療のための、フェニルアミノチオフェン酢酸誘導体を含有する組成物
US6982075B2 (en) Use of pulmonary surfactant
HK1026145B (en) A composition for the treatment of irds and ards
DE19705924A1 (de) Neue Zusammensetzungen

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

AMND Amendment
J201 Request for trial against refusal decision
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

PB0901 Examination by re-examination before a trial

St.27 status event code: A-6-3-E10-E12-rex-PB0901

B601 Maintenance of original decision after re-examination before a trial
PB0601 Maintenance of original decision after re-examination before a trial

St.27 status event code: N-3-6-B10-B17-rex-PB0601

J301 Trial decision

Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20050727

Effective date: 20060919

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20060919

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 1999 7007400

Appeal request date: 20050727

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2005101004880

PS0901 Examination by remand of revocation

St.27 status event code: A-6-3-E10-E12-rex-PS0901

S901 Examination by remand of revocation
GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

St.27 status event code: A-3-4-F10-F13-rex-PS0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20121009

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

FPAY Annual fee payment

Payment date: 20131001

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

FPAY Annual fee payment

Payment date: 20141006

Year of fee payment: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

FPAY Annual fee payment

Payment date: 20150918

Year of fee payment: 10

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

FPAY Annual fee payment

Payment date: 20160921

Year of fee payment: 11

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 11

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20171025

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20171025